GSA Capital Partners LLP Boosts Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

GSA Capital Partners LLP increased its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 76.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,104 shares of the company’s stock after purchasing an additional 14,343 shares during the quarter. GSA Capital Partners LLP’s holdings in Centessa Pharmaceuticals were worth $828,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares during the last quarter. DNB Asset Management AS purchased a new stake in Centessa Pharmaceuticals during the third quarter worth approximately $218,000. Sigma Planning Corp purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $225,000. Finally, BNP Paribas Financial Markets lifted its stake in Centessa Pharmaceuticals by 3,028.1% during the second quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock worth $460,000 after purchasing an additional 33,854 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

CNTA has been the subject of several recent analyst reports. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research note on Monday, April 13th. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their target price for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Finally, Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $35.00 to $42.00 in a research note on Monday, April 20th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $40.70.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $39.75 on Friday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $10.95 and a twelve month high of $40.26. The stock has a 50 day moving average of $36.56 and a two-hundred day moving average of $29.36. The stock has a market cap of $5.93 billion, a P/E ratio of -22.21 and a beta of 1.13.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the sale, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 309,112 shares of company stock valued at $8,424,535. 4.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.